

CIP E
 JUL 28 2003
 PATENT & TRADEMARK OFFICE

PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete If Known			
		Application Number	09/724,288		
		Filing Date	November 28, 2000		
		First Named Inventor	Schenk, Dale B.		
		Art Unit	1647		
		Examiner Name	Sharon Turner		
Page	1	of	1	Attorney Docket Number	15270J-004765US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/KAB/	349	CHECK, "Battle of the Mind," <u>Nature</u> , 422:370-372 (March 2003).	
/KAB/	350	Nicoll et al., "Neuropathology of human Alzheimer's disease after immunization with amyloid- β peptide: a case report," <u>Nature Medicine</u> , 9(4):448-452 (April 2003).	

RECEIVED

AUG 01 2003

TECH CENTER 1600/2900

Examiner Signature	/Kimberly Ballard/	Date Considered	04/14/2007
--------------------	--------------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet **1** of **6****Complete if Known**

Application Number	09/724,288
Filing Date	November 28, 2000
First Named Inventor	Schenk, Dale B.
Art Unit	1649
Examiner Name	Kimberly A. Ballard
Attorney Docket Number	15270J-004765US


U.S. PATENT DOCUMENTS+

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (if known)			
/KAB/	785	2005/0249725 A1	11-10-2005	Schenk et al.	
	758	2005/0169925 A1	08-04-2005	Bardroff et al.	
	784	2005/0118651 A1	06-02-2005	Basi et al.	
	805	2004/0197324 A1	10-07-2004	Jun et al.	
	783	2004/0087777 A1	05-06-2004	Basi et al.	
	782	2004/0082762 A1	04-29-2004	Basi et al.	
	804	2003/0202972 A1	10-30-2003	James et al.	
	748	6,610,493	08-26-2003	Citron et al.	
	776	6,372,716	04-16-2002	Bush et al.	
	777	6,270,757	08-07-2001	Warne	
	778	6,267,958	07-31-2001	Andya et al.	
	795	6,210,671	04-03-2001	Co	
	747	6,175,057	01-16-2001	Mucke et al.	
	771	5,837,268	11-17-1998	Potter et al.	
	779	5,770,700	06-23-1998	Webb et al.	
	780	5,744,132	04-28-1998	Warne et al.	
	770	5,733,548	03-31-1998	Restifo et al.	
	764	5,601,827	02-11-1997	Collier et al.	
	781	5,385,887	01-31-1995	Yim et al.	
	819	5,227,159	07-13-1993	Miller	
	740	4,883,666	11-28-1989	Sabel et al.	
	763	60/067,740	filed 12-02-1997	Schenk	
	760	60/067,219	filed 12-03-1997	Weiner et al.	
	761	60/079,697	filed 03-27-1998	Weiner et al.	
/KAB/	762	60/080,970	filed 01-11-1999	Schenk	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.
60814886 / 51175-1

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/724,288
				Filing Date	November 28, 2000
				First Named Inventor	Schenk, Dale B.
				Art Unit	1649
				Examiner Name	Kimberly A. Ballard
Sheet	2	of	6	Attorney Docket Number	15270J-004765US

FOREIGN PATENT DOCUMENTS									
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶	
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)					
/KAB/	786	EP	758 901	B1	02-26-1997				
	787	EP	758 248	B1	02-19-1997				
	802	EP	597 101	A1	05-18-1994				
	820	EP	285 159	A1	10-05-1988				
	757	WO	04/108895	A2, A3	12-16-2004				
	797	WO	04/055164	A2	07-01-2004				
	796	WO	03/105894	A1	12-24-2003				
	799	WO	03/39485	A2	05-15-2003				
	756	WO	03/16467	A2, A3	02-27-2003				
	788	WO	03/15691	A2	02-27-2003				
	803	WO	03/16466	A2	02-27-2003				
	798	WO	03/09817	A2	02-06-2003				
	827	WO	02/96937	A2	12-05-2002				
	789	WO	01/05355	A2	01-25-2001				
	772	WO	99/10008	A1	03-04-1999				
	813	WO	97/03192	A3	01-30-1997				
	814	WO	94/00153	A1	01-06-1994				
	/KAB/	821	WO	91/16928	A1	11-14-1991			

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.
60814886 / 51175-1

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	09/724,288	
			Filing Date	November 28, 2000	
			First Named Inventor	Schenk, Dale B.	
			Art Unit	1649	
			Examiner Name	Kimberly A. Ballard	
Sheet	3	of	6	Attorney Docket Number	15270J-004765US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/KAB/	773	ALBERTS.ET AL., <i>Molecular Biology of the Cell</i> , 2nd Edition, pages 266-267, Garland Publishing Inc., New York (1989).	
	790	DALES et al., "Administration of an Anti-Aβ Fab Fragment to APP^{V717F} Transgenic Mice Reduces Neuritic Plaque," Abstract P5-396, Page 6587, presented at Poster Session P4: Therapeutics and Therapeutic Strategies-Therapeutic Strategies, Amyloid-Based	
/KAB/	750	BICKEL et al., "Development and in Vitro Characterization of a Cationized Monoclonal Antibody against β A4 Protein: A Potential Probe for Alzheimer's Disease," <i>Bioconjugate Chem.</i> , 5:119-125 (1994).	
	754	BLASBERG et al., "Regional Localization of Glioma-associated Antigen Defined by Monoclonal Antibody 81C6 <i>in Vivo</i> : Kinetics and Implications for Diagnosis and Therapy," <i>Cancer Research</i> , 47:4432-4443 (1987).	
	824	BROOKMEYER et al., "Projections of Alzheimer's Disease in the United States and the Public Health Impact of Delaying Disease Onset," <i>Am. J. Public Health</i> , 88:1337-1342 (1998).	
	791	BUSSIERE et al., "Morphological Characterization of Thioflavin-S-Positive Amyloid Plaques in Transgenic Alzheimer Mice and Effect of Passive A β Immunotherapy on Their Clearance," <i>Am. J. Pathology</i> , 165(3):987-995 (2004).	
	823	CASELL et al., "Demography and Epidemiology of Age-Associated Neuronal Impairment," chapter 4, pages 31-50 from <i>Functional Neurobiology of Aging</i> , Hof et al., eds., Academic Press (2001).	
	766	COICO et al., <i>Immunology A Short Course, Fifth Edition</i> , pages 18-24 (2003).	
	769	DAVIS, S. S., "Nasal Vaccines," <i>Advanced Drug Delivery Reviews</i> , 51:21-42 (2001).	
	817	DU et al., " α_2 -Macroglobulin as a β -Amyloid Peptide-Binding Plasma Protein," <i>J. Neurochemistry</i> , 69(1):299-305 (1997).	
	811	European Search Report of 5/22/06 for European Application 06075704.4-2107.	
	812	European Search REport of 5/22/06 for European Application 06075479.3-2107.	
	807	HARA et al., "Development of a safe oral A β vaccine using recombinant adeno-associated virus vector for Alzheimer's disease," <i>J. Alzheimer's Disease</i> , 6:483-488 (2004).	
/KAB/	741	HIRSCHFIELD et al., "Amyloidosis: new strategies for treatment," <i>Int. J. Biochem. & Cell Biol.</i> , 35:1608-1613 (2003).	

No date
or sourc
info. Do
not prin

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	09/724,288	
			Filing Date	November 28, 2000	
			First Named Inventor	Schenk, Dale B.	
			Art Unit	1649	
			Examiner Name	Kimberly A. Ballard	
Sheet	4	of	6	Attorney Docket Number	15270J-004765US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/KAB/	792	KAJKOWSKI et al., "β-Amyloid Peptide-induced Apoptosis Regulated by a Novel Protein Containing a G Protein Activation Module," <u>J. Biol. Chem.</u> , 276(22):18748-18756 (2001).	
	794	KOFLER et al., "Immunoglobulin κ Light Chain Variable Region Gene Complex Organization and Immunoglobulin Genes Encoding Anti-DNA Autoantibodies in Lupus Mice," <u>J. Clin. Invest.</u> , 82:852-860 (1988).	
	826	KUBY, J., eds., page 123 from <i>Immunology, Third Edition</i> , W.H. Freeman & co., (1997).	
	816	LaDu et al., "Isoform-specific Binding of Apolipoprotein E to β-Amyloid," <u>J. Biol. Chem.</u> , 269(38):23403-23406 (1994).	
	755	LAVIE et al., "EFRH-Phage Immunization of Alzheimer's Disease Animal Model Improves Behavioral Performance in Morris Water Maze Trials," <u>J. Molecular Neuroscience</u> , 24:105-113 (2004).	
	743	LICASTRO et al., "Is immunotherapy an effective treatment for Alzheimer's disease?," <u>Immunity & Aging</u> , 1:1-2 (2004).	
	742	MANOJ et al., "Approaches to Enhance the Efficacy of DNA Vaccines," <u>Critical Rev. Clin. Lab. Sci.</u> , 41(1):1-39 (2004).	
	744	MAROTTA et al., "Overexpression of amyloid precursor protein A4 (β-amyloid) immunoreactivity in genetically transformed cells: Implications for a cellular model of Alzheimer amyloidosis," <u>PNAS</u> , 86:337-341 (1989).	
	822	Merriam-Webster online medical dictionary, entry for "cure", accessed September 5, 2006.	
	808	OKURA et al., "Nonviral Aβ DNA vaccine therapy against Alzheimer's disease: Long-term effect and safety," <u>PNAS</u> , 103(25):9619-9624 (2006).	
	806	PCT Search Report of 8/11/06 for application PCT/US2006/002837.	
	774	PEETERS et al., "Comparison of four bifunctional reagents for coupling peptides to proteins and the effect of the three moieties on the immunogenicity of the conjugates," <u>J. Immunological Methods</u> , 120:133-143 (1989).	
↓	751	PROBERT et al., "Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of tumor necrosis factor α," <u>PNAS</u> , 92:11294-11298 (1995).	
/KAB/	809	QU et al., "Aβ ₄₂ gene vaccination reduces brain amyloid plaque burden in transgenic mice," <u>J. Neurological Sciences</u> , 244:151-158 (2006).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	09/724,288	
			Filing Date	November 28, 2000	
			First Named Inventor	Schenk, Dale B.	
			Art Unit	1649	
			Examiner Name	Kimberly A. Ballard	
Sheet	5	of	6	Attorney Docket Number	15270J-004765US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/KAB/	759	SCHENK et al., "Current progress in beta-amyloid immunotherapy," <u>Curr. Opin. Immunology</u> , 16(5):599-606 (2004).	
	768	SCHMITT et al., "Interactions of the alzheimer β amyloid fragment ₍₂₅₋₃₅₎ with peripheral blood dendritic cells," <u>Mechanisms of Ageing and Development</u> , 94:223-232 (1997).	
	818	SHINKAI et al., "Amyloid β -Proteins 1-40 and 1-42(43) in the Soluble Fraction of Extra- and Intracranial Blood Vessels," <u>Ann. Neurol.</u> , 38:421-428 (1995).	
	767	TRIEB et al., "APP Peptides Stimulate Lymphocyte Proliferation in Normals, But Not in Patients With Alzheimer's Disease," <u>Neurobiology of Aging</u> , 17(4):541-547 (1996).	
	815	URMONEIT et al., "Cerebrovascular Smooth Muscle Cells Internalize Alzheimer Amyloid Beta Protein via a Lipoprotein Pathway: Implications for Cerebral Amyloid Angiopathy," <u>Laboratory Investigation</u> , 77(2):157-166 (1997).	
	775	VAN DEN DOBBELSTEEN et al., "Characteristics of Immune Responses to Native and Protein Conjugated Pneumococcal Polysaccharide Type 14," <u>Scand. J. Immunol.</u> , 41:273-280 (1995).	
	800	VIDANOVIC et al., "Effects of nonionic surfactants on the physical stability of immunoglobulin G in aqueous solution during mechanical agitation," <u>DIE PHARMAZIE</u> , 58(6):399-404 (2003).	
	801	WANG, W., "Instability, stabilization, and formulation of liquid protein pharmaceuticals," <u>Int. J. Pharmaceutics</u> , 185(2):129-188 (1999).	
	765	WEINER, H. L., "Oral tolerance: immune mechanisms and treatment of autoimmune diseases," <u>Immunology Today</u> , 18:335-343 (1997).	
	739	WEINREB et al., "NACP, A Protein Implicated in Alzheimer's Disease and Learning, Is Natively Unfolded," <u>Biochemistry</u> , 35(43):13709-13715 (1996).	
	749	Wikipedia definition of "epitope" printed from internet on 4/26/06.	
	752	Wikipedia definition of "antigen" printed from internet on 4/26/06.	
/KAB/	753	Wikipedia definition of "route of administration including parenteral" printed from internet on 4/26/06.	
	793	ZAMEER et al., "Single Chain Fv Antibodies against 25-35 Peptide Fragment of Amyloid-β: Potential Therapeutic for Alzheimer's Disease," Abstract P4-420, Page S593, presented at Poster Session P4:Therapeutics and Therapeutic Strategies-Therapeutic Strategies, Amyloid-Based No source or publication date. Do not print.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	09/724,288
				Filing Date	November 28, 2000
				First Named Inventor	Schenk, Dale B.
				Art Unit	1649
				Examiner Name	Kimberly A. Ballard
Sheet	6	of	6	Attorney Docket Number	15270J-004765US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/KAB/	810	ZHANG et al., "A novel recombinant adeno-associated virus vaccine reduces behavioral impairment and β -amyloid plaques in a mouse model of Alzheimer's disease," <u>Neurobiology of Disease</u> , 14:365-379 (2003).	
/KAB/	825	ZHANG et al., "Specialized Applications, Purification of Recombinant Proteins and Study of Protein Interaction by Epitope Tagging," <u>Current Protocols in Mol. Biol.</u> , Supp 41, pages 10.15.1 through 10.15.9 (1998).	

Examiner Signature	/Kimberly Ballard/	Date Considered	04/14/2007
-----------------------	--------------------	--------------------	------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.